Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology Study 1055)

Background: In patients with anaplastic lymphoma kinase (ALK) rearrangement-positive advanced non–small-cell lung cancer (NSCLC), ALK inhibitors are now the standard treatment, but their clinical efficacy varies widely for each patient. In this multicenter retrospective study, we evaluated the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Meichen, Hou, Xue, Zhou, Chengzhi, Feng, Weineng, Jiang, Guanming, Long, Hao, Yang, Shuang, Chen, Jing, Wang, Na, Wang, Kaicheng, Chen, Likun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471725/
https://www.ncbi.nlm.nih.gov/pubmed/32974126
http://dx.doi.org/10.3389/fonc.2020.01216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471725/
https://www.ncbi.nlm.nih.gov/pubmed/32974126
http://dx.doi.org/10.3389/fonc.2020.01216

Ejemplares similares